Sanofi-B (02257) has completed the Phase I clinical trial of the investigational drug STP707 and has officially submitted the clinical study report to the FDA.

Zhtng Cijng APP News, Sinovac Biotech Ltd. (02257) announced that its wholly-owned subsidiary, Sirnaomics, Inc., has completed Phase I clinical trials for the investigational drug STP707 and has officially submitted the clinical study report to the U.S. Food and Drug Administration (FDA).